Syndax Pharmaceuticals, Inc.
SNDX
$19.84
$0.763.98%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 252.25M | 217.42M | 172.60M | 111.55M | 78.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 252.25M | 217.42M | 172.60M | 111.55M | 78.18M |
| Cost of Revenue | 272.45M | 264.71M | 265.75M | 250.76M | 263.35M |
| Gross Profit | -20.20M | -47.29M | -93.16M | -139.21M | -185.17M |
| SG&A Expenses | 173.97M | 176.24M | 179.68M | 167.44M | 153.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 446.42M | 440.95M | 445.44M | 418.21M | 416.99M |
| Operating Income | -194.17M | -223.53M | -272.84M | -306.65M | -338.81M |
| Income Before Tax | -220.77M | -243.25M | -285.42M | -311.58M | -334.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -220.77 | -243.25 | -285.42 | -311.58 | -334.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -220.77M | -243.25M | -285.42M | -311.58M | -334.99M |
| EBIT | -194.17M | -223.53M | -272.84M | -306.65M | -338.81M |
| EBITDA | -194.16M | -223.52M | -272.83M | -306.65M | -338.80M |
| EPS Basic | -2.52 | -2.80 | -3.30 | -3.62 | -3.90 |
| Normalized Basic EPS | -1.57 | -1.75 | -2.06 | -2.26 | -2.44 |
| EPS Diluted | -2.52 | -2.80 | -3.30 | -3.62 | -3.90 |
| Normalized Diluted EPS | -1.57 | -1.75 | -2.06 | -2.26 | -2.44 |
| Average Basic Shares Outstanding | 351.23M | 348.57M | 346.49M | 344.92M | 343.73M |
| Average Diluted Shares Outstanding | 351.23M | 348.57M | 346.49M | 344.92M | 343.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |